Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
作者信息
Martinez Miguel Angel
机构信息
IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
出版信息
Front Immunol. 2021 Mar 11;12:635371. doi: 10.3389/fimmu.2021.635371. eCollection 2021.
Abstract
摘要
相似文献
1
Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.用于治疗新冠病毒病的重新利用药物缺乏有效性。
Front Immunol. 2021 Mar 11;12:635371. doi: 10.3389/fimmu.2021.635371. eCollection 2021.
2
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.重新利用药理学药物治疗 COVID-19 的潜力：文献综述。
Respir Res. 2021 Nov 27;22(1):304. doi: 10.1186/s12931-021-01885-8.
3
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites.当前 COVID-19 治疗药物的衍生化和联合治疗：对作用机制途径、不良反应和结合部位的综述。
Drug Discov Today. 2020 Oct;25(10):1822-1838. doi: 10.1016/j.drudis.2020.08.002. Epub 2020 Aug 12.
4
The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.中药抗击新冠疫情的挑战与机遇：基于网络视角的出路
Acta Pharmacol Sin. 2021 Jun;42(6):845-847. doi: 10.1038/s41401-021-00645-0. Epub 2021 Apr 13.
5
Ensuring continued progress for development of COVID-19 therapeutics in children.确保儿童新冠治疗药物研发持续取得进展。
Pediatr Res. 2021 Dec;90(6):1112-1114. doi: 10.1038/s41390-021-01384-y. Epub 2021 Feb 18.
6
Cutaneous lesions and COVID-19: Cystic painful lesion in a case with positive SARS-CoV-2.皮肤病变与新型冠状病毒肺炎：1例严重急性呼吸综合征冠状病毒2（SARS-CoV-2）检测阳性病例的囊性疼痛性病变
Dermatol Ther. 2020 Nov;33(6):e14266. doi: 10.1111/dth.14266. Epub 2020 Sep 14.
7
Fighting COVID-19 with Artificial Intelligence.运用人工智能抗击新冠疫情。
Methods Mol Biol. 2022;2390:103-112. doi: 10.1007/978-1-0716-1787-8_3.
8
Alopecia areata in a patient with SARS-Cov-2 infection.一名感染新型冠状病毒肺炎（SARS-CoV-2）的患者出现斑秃。
Dermatol Ther. 2020 Nov;33(6):e14295. doi: 10.1111/dth.14295. Epub 2020 Sep 21.
9
Immune interventions in COVID-19: a matter of time?COVID-19 的免疫干预：时间问题？
Mucosal Immunol. 2022 Feb;15(2):198-210. doi: 10.1038/s41385-021-00464-w. Epub 2021 Oct 28.
10
Adverse drug reactions associated with COVID-19 management.与 COVID-19 管理相关的药物不良反应。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7353-7376. doi: 10.1007/s00210-024-03137-0. Epub 2024 May 14.
引用本文的文献
1
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.解锁见解：应对新冠疫情挑战并通过增强自然免疫力效仿未来大流行的韧性策略。
Heliyon. 2024 Jul 17;10(15):e34691. doi: 10.1016/j.heliyon.2024.e34691. eCollection 2024 Aug 15.
2
Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial.一种新型抗病毒草药制剂用于新冠肺炎重症监护病房患者的疗效与安全性：一项III期双盲对照试验。
Avicenna J Phytomed. 2024 Mar-Apr;14(2):215-228. doi: 10.22038/AJP.2023.23259.
3
Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia.关键患者人口统计学特征塑造非危重症低氧 COVID-19 肺炎的固有免疫图谱。
JCI Insight. 2023 Aug 22;8(16):e166110. doi: 10.1172/jci.insight.166110.
4
De Novo Design of Anti-COVID Drugs Using Machine Learning-Based Equivariant Diffusion Model Targeting the Spike Protein.基于针对刺突蛋白的机器学习等变扩散模型的抗新冠病毒药物的从头设计
Curr Issues Mol Biol. 2023 May 12;45(5):4261-4284. doi: 10.3390/cimb45050271.
5
Cyclophilin A-mediated mitigation of coronavirus SARS-CoV-2.亲环素A介导的新型冠状病毒SARS-CoV-2缓解作用
Bioeng Transl Med. 2023 Mar;8(2):e10436. doi: 10.1002/btm2.10436. Epub 2022 Oct 27.
6
Adapting an integrated acute respiratory infections sentinel surveillance to the COVID-19 pandemic requirements, Egypt, 2020-2022.2020 - 2022年，埃及根据新冠疫情要求调整综合急性呼吸道感染哨点监测。
Public Health Pract (Oxf). 2023 Jun;5:100358. doi: 10.1016/j.puhip.2023.100358. Epub 2023 Jan 18.
7
Comparative docking studies of drugs and phytocompounds for emerging variants of SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）新出现变体的药物和植物化合物的比较对接研究。
3 Biotech. 2023 Jan;13(1):36. doi: 10.1007/s13205-022-03450-6. Epub 2023 Jan 5.
8
Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review.生物活性化合物作为针对 COVID-19 的潜在血管紧张素转化酶 II 抑制剂：范围综述。
Inflamm Res. 2022 Dec;71(12):1489-1500. doi: 10.1007/s00011-022-01642-7. Epub 2022 Oct 28.
9
Systematic Down-Selection of Repurposed Drug Candidates for COVID-19.用于 COVID-19 的再利用药物候选物的系统降阶。
Int J Mol Sci. 2022 Oct 6;23(19):11851. doi: 10.3390/ijms231911851.
10
Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants.破解新冠病毒（COVID-19）宿主转录组的复杂性及变异，以发现针对新变种的治疗方法。
iScience. 2022 Oct 21;25(10):105068. doi: 10.1016/j.isci.2022.105068. Epub 2022 Sep 3.
本文引用的文献
1
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.伊维菌素早期治疗对非重症 COVID-19 患者病毒载量、症状及体液反应的影响：一项试点、双盲、安慰剂对照、随机临床试验。
EClinicalMedicine. 2021 Feb;32:100720. doi: 10.1016/j.eclinm.2020.100720. Epub 2021 Jan 19.
2
Recent progress in the repurposing of drugs/molecules for the management of COVID-19.近期药物/分子再利用以管理 COVID-19 的进展。
Expert Rev Anti Infect Ther. 2021 Jul;19(7):889-897. doi: 10.1080/14787210.2021.1860020. Epub 2020 Dec 10.
3
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
4
Latin America's embrace of an unproven COVID treatment is hindering drug trials.拉丁美洲对一种未经证实的新冠治疗方法的接受正在阻碍药物试验。
Nature. 2020 Oct;586(7830):481-482. doi: 10.1038/d41586-020-02958-2.
5
Repurposing existing drugs for COVID-19: an endocrinology perspective.重新利用现有药物治疗 COVID-19：内分泌学视角。
BMC Endocr Disord. 2020 Sep 29;20(1):149. doi: 10.1186/s12902-020-00626-0.
6
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
7
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.一项关于法匹拉韦早期与晚期治疗对COVID-19住院患者疗效的前瞻性、随机、开放标签试验。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01897-20.
8
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
9
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
10
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.中和抗体与高感染率渔业船舶暴发期间人类免受 SARS-CoV-2 感染相关。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.02107-20.
Zotero 插件